Mahalakshmi Radhakrishnan's most recent trade in Candel Therapeutics Inc was a trade of 28,480 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | Mahalakshmi Radhakrishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 28,480 | 28,480 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Mahalakshmi Radhakrishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2025 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Alto Neuroscience Inc. | Mahalakshmi Radhakrishnan | Director | 08 Mar 2024 | 30,574 | 30,574 | - | - | Stock Option (right to buy) | ||
| Alto Neuroscience Inc. | Mahalakshmi Radhakrishnan | Director | 08 Mar 2024 | 1,590 | 1,590 | - | - | Stock Option (right to buy) |